Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 666

1.

Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.

Jacobsen P, Andersen S, Jensen BR, Parving HH.

J Am Soc Nephrol. 2003 Apr;14(4):992-9.

PMID:
12660333
[PubMed - indexed for MEDLINE]
Free Article
2.

Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.

Jacobsen P, Andersen S, Rossing K, Jensen BR, Parving HH.

Kidney Int. 2003 May;63(5):1874-80.

PMID:
12675866
[PubMed - indexed for MEDLINE]
3.

Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy.

Jacobsen P, Andersen S, Rossing K, Hansen BV, Parving HH.

Nephrol Dial Transplant. 2002 Jun;17(6):1019-24.

PMID:
12032191
[PubMed - indexed for MEDLINE]
Free Article
4.

Additive hypotensive effect of angiotensin-converting enzyme inhibition and angiotensin-receptor antagonism in essential hypertension.

Stergiou GS, Skeva II, Baibas NM, Roussias LG, Kalkana CB, Achimastos AD, Mountokalakis TD.

J Cardiovasc Pharmacol. 2000 Jun;35(6):937-41.

PMID:
10836730
[PubMed - indexed for MEDLINE]
5.

Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy.

Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH.

Kidney Int. 2000 Feb;57(2):601-6.

PMID:
10652037
[PubMed - indexed for MEDLINE]
Free Article
6.

Combination of hydrochlorothiazide or benazepril with valsartan in hypertensive patients unresponsive to valsartan alone.

Waeber B, Aschwanden R, Sadecky L, Ferber P.

J Hypertens. 2001 Nov;19(11):2097-104.

PMID:
11677377
[PubMed - indexed for MEDLINE]
7.

Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease.

Ruilope LM, Aldigier JC, Ponticelli C, Oddou-Stock P, Botteri F, Mann JF.

J Hypertens. 2000 Jan;18(1):89-95.

PMID:
10678548
[PubMed - indexed for MEDLINE]
8.

Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study.

Rossing K, Christensen PK, Jensen BR, Parving HH.

Diabetes Care. 2002 Jan;25(1):95-100.

PMID:
11772908
[PubMed - indexed for MEDLINE]
9.

Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone.

Schjoedt KJ, Jacobsen P, Rossing K, Boomsma F, Parving HH.

Horm Metab Res. 2005 Apr;37 Suppl 1:4-8.

PMID:
15918104
[PubMed - indexed for MEDLINE]
10.

Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study.

Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, Parving HH.

Diabetes Care. 2005 Sep;28(9):2106-12.

PMID:
16123474
[PubMed - indexed for MEDLINE]
11.

Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?

Weir MR.

Clin Ther. 2007 Sep;29(9):1803-24. Review.

PMID:
18035185
[PubMed - indexed for MEDLINE]
12.

Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect.

Viberti G, Wheeldon NM; MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators.

Circulation. 2002 Aug 6;106(6):672-8.

PMID:
12163426
[PubMed - indexed for MEDLINE]
Free Article
13.

Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial.

Rossing K, Jacobsen P, Pietraszek L, Parving HH.

Diabetes Care. 2003 Aug;26(8):2268-74.

PMID:
12882847
[PubMed - indexed for MEDLINE]
14.
15.

Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points.

Parving HH, Andersen S, Jacobsen P, Christensen PK, Rossing K, Hovind P, Rossing P, Tarnow L.

Semin Nephrol. 2004 Mar;24(2):147-57. Review.

PMID:
15017527
[PubMed - indexed for MEDLINE]
16.

Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy.

Jacobsen P, Rossing K, Parving HH.

Curr Opin Nephrol Hypertens. 2004 May;13(3):319-24. Review.

PMID:
15073491
[PubMed - indexed for MEDLINE]
17.

Dual blockade of the renin-angiotensin system in diabetic nephropathy.

Wade VL, Gleason BL.

Ann Pharmacother. 2004 Jul-Aug;38(7-8):1278-82. Epub 2004 Jun 8. Review.

PMID:
15187210
[PubMed - indexed for MEDLINE]
18.

ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group.

Bakris GL, Siomos M, Richardson D, Janssen I, Bolton WK, Hebert L, Agarwal R, Catanzaro D.

Kidney Int. 2000 Nov;58(5):2084-92.

PMID:
11044229
[PubMed - indexed for MEDLINE]
Free Article
19.

Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment.

Rossing P, Tarnow L, Boelskifte S, Jensen BR, Nielsen FS, Parving HH.

Diabetes. 1997 Mar;46(3):481-7.

PMID:
9032106
[PubMed - indexed for MEDLINE]
20.

Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy.

Tarnow L, Rossing P, Jensen C, Hansen BV, Parving HH.

Diabetes Care. 2000 Dec;23(12):1725-30.

PMID:
11128341
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk